Reversal of Ventricular Remodeling With Toprol-XL
2 other identifiers
interventional
300
1 country
44
Brief Summary
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Aug 2001
44 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2001
CompletedFirst Submitted
Initial submission to the registry
May 28, 2002
CompletedFirst Posted
Study publicly available on registry
May 29, 2002
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2003
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2003
CompletedNovember 19, 2010
November 1, 2010
2.1 years
May 28, 2002
November 17, 2010
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Diagnosis of stable asymptomatic heart failure.
- Documented ejection fraction less than 0.40.
- Must be able to comply with all study procedures.
You may not qualify if:
- Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization.
- Have heart problems that would not allow B-blocker therapy.
- Receiving B-blockers therapy for any medical reason including topical B-blockers that might cause systemic absorption (e.g., glaucoma).
- Undergone certain heart surgeries, such as, prior heart transplant or cardiomyoplasty.
- Have certain heart diseases.
- Pregnant or breast feeding.
- Unlikely to survive.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (44)
Unknown Facility
Birmingham, Alabama, United States
Unknown Facility
Mobile, Alabama, United States
Unknown Facility
Little Rock, Arkansas, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
Northridge, California, United States
Unknown Facility
Redondo Beach, California, United States
Unknown Facility
Riverside, California, United States
Research Site
Farmington, Connecticut, United States
Unknown Facility
Clearwater, Florida, United States
Unknown Facility
Melbourne, Florida, United States
Unknown Facility
Vero Beach, Florida, United States
Unknown Facility
Augusta, Georgia, United States
Unknown Facility
Indianapolis, Indiana, United States
Unknown Facility
Jeffersonville, Indiana, United States
Unknown Facility
Edgewood, Kentucky, United States
Unknown Facility
New Orleans, Louisiana, United States
Unknown Facility
Shreveport, Louisiana, United States
Unknown Facility
Auburn, Maine, United States
Unknown Facility
Baltimore, Maryland, United States
Unknown Facility
Salisbury, Maryland, United States
Unknown Facility
Boston, Massachusetts, United States
Unknown Facility
Saint Charles, Missouri, United States
Unknown Facility
St Louis, Missouri, United States
Unknown Facility
Omaha, Nebraska, United States
Unknown Facility
Albuquerque, New Mexico, United States
Unknown Facility
Buffalo, New York, United States
Unknown Facility
East Syracuse, New York, United States
Unknown Facility
New York, New York, United States
Unknown Facility
Rochester, New York, United States
Unknown Facility
The Bronx, New York, United States
Unknown Facility
Williamsville, New York, United States
Unknown Facility
Burlington, North Carolina, United States
Unknown Facility
Columbus, Ohio, United States
Unknown Facility
Oklahoma City, Oklahoma, United States
Unknown Facility
Flourtown, Pennsylvania, United States
Unknown Facility
Philadelphia, Pennsylvania, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Lincoln, Rhode Island, United States
Unknown Facility
Wakefield, Rhode Island, United States
Unknown Facility
Tyler, Texas, United States
Unknown Facility
Salt Lake City, Utah, United States
Unknown Facility
Chesapeake, Virginia, United States
Unknown Facility
Roanoke, Virginia, United States
Unknown Facility
Green Bay, Wisconsin, United States
Related Publications (1)
Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation. 2007 Jul 3;116(1):49-56. doi: 10.1161/CIRCULATIONAHA.106.666016. Epub 2007 Jun 18.
PMID: 17576868DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 28, 2002
First Posted
May 29, 2002
Study Start
August 1, 2001
Primary Completion
September 1, 2003
Study Completion
September 1, 2003
Last Updated
November 19, 2010
Record last verified: 2010-11